"VIVALIS is an ideal vaccine development partner, with a strong commercial mindset, a history of successful partnerships and great technology in the internationally established EB66 cell line. We are excited to be beginning this collaboration and moving forward on the LAIV vector project" said Mr Julie Phillips, CEO, BioDiem.

Mr Franck Grimaud, CEO, and Mr Majid Mehtali, CSO, who are the co-managers of VIVALIS jointly stated that, "Advancing the EB66 platform into novel areas is an objective we have maintained from the initial launch of the platform. This agreement with BioDiem, the second EB66 agreement since January 1, continues these objectives by moving our EB66 technology into applications like those being developed by BioDiem in the therapeutic and preventative vaccine fields. We look forward to working with BioDiem in this program and the possibility of expanding our relationship into a process development, a future commercial license and biomanufacturing agreement as we both advance the field of vaccine design and development."